Evidence map›Paper›PMID 42065115›Full record

ArticleMolecular therapy. Nucleic acids2026

Broad-spectrum CRISPR-Cas13d-mediated strategy for combating human coronaviruses.

Zhenghao Yu, Mouraya Hussein, Yuanling Bao, Ana Alcalá-Lalinde, Pascal Zion Kroon, Eva Thuillier, Zhi Zhang, Luis Enjuanes, Sonia Zuñiga, Ben Berkhout and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhenghao YuAmsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, the Netherlands.
Mouraya HusseinAmsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, the Netherlands.
Yuanling BaoAmsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, the Netherlands.
Ana Alcalá-LalindeAmsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, the Netherlands.
Pascal Zion KroonAmsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, the Netherlands.
Eva ThuillierAmsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, the Netherlands.
Zhi ZhangInstitute for Logic, Language and Computation (ILLC), University of Amsterdam, Amsterdam, the Netherlands.
Luis EnjuanesDepartment of Molecular and Cell Biology, National Center of Biotechnology (CNB-CSIC), Darwin 3, Madrid, Spain.
Sonia ZuñigaDepartment of Molecular and Cell Biology, National Center of Biotechnology (CNB-CSIC), Darwin 3, Madrid, Spain.
Ben BerkhoutAmsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, the Netherlands.
Elena Herrera-CarrilloAmsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Meibergdreef 9, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA viruses evolve rapidly, enabling them to evade host immunity and antiviral therapies and complicating durable diagnostics strategies. There is a pressing need for approaches that provide broad-spectrum viral suppression and detection. We designed four Cas13d crRNAs targeting a conserved 26-nucleotide sequence in coronavirus (CoV) nsp12. Their antiviral efficacy was evaluated

Indexed as

antiviralcoronavirusCRISPR-Cas13ddiagnosticMT: RNA/DNA editingpandemic preparednesspoint-of-care testingSHERLOCK

Identifiers

PMID42065115
PMCPMC13126349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.